Date:4/29/2009

ome taxes - - Net income (loss)(b) $129,813 $(52,719) Basic net income (loss) per share $0.96 $(0.39) Diluted net income (loss) per share $0.85 $(0.39) Weighted average shares outstanding, basic 135,755,471 135,284,778 Weighted average shares outstanding, diluted 163,423,487 135,284,778 (a) Includes stock-based compensation expense of $2,935 ($0.02 per basic and diluted share) and $4,463 ($0.03 per basic and diluted share) for the three months ended March 31, 2009 and 2008, respectively. (b) HGS adopted FASB Staff Position No. APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) ("FSP APB 14-1") effective January 1, 2009, which required restatement of prior periods, as applicable. Includes amortization of debt discount of $6,398 ($0.05 per basic share and $0.04 per diluted share) for the three months ended March 31, 2009. 2008 results have been restated and now include amortization of debt discount of $5,854 ($0.04 per basic and diluted share) for the three months ended March 31, 2008. Results for 2009 and 2008 also include certain other immaterial adjustments arising from the adoption of FSP APB 14-1. CONSOLIDATED BALANCE SHEET DATA: As of As of March 31, 2009 December 31, 2008(c) (dollars in thousands) Cash, cash equivalents and investments (d) $396,852 $372,939 Total assets (d) 735,365 6
'/>"/>

SOURCE Human Genome Sciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources